Comments

Immunovant Stock Price, Quotes and Forecasts

Q: What sector and industry does Immunovant (IMVT) operate in?

Immunovant is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

IMVTNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$13.31

At close: Apr 8 EDT

$13.00

-0.31-2.33%

Pre-Market: 5:10 PM EDT

Immunovant (IMVT) Forecast

News Earnings Immunovant (IMVT) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Immunovant Stock Price, Quotes and Forecasts | NASDAQ:IMVT | Benzinga

Explore Immunovant stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for IMVT.

Open	-
Close	-
Volume / Avg.	0 / 1.68M
Day Range	- - -
52 Wk Range	13.08 - 34.47
Market Cap	$2.21B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	24
Short Interest	18.06%
Days to Cover	14.48

Recent News

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.

Vandana Singh

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

Shares of Immunovant (NASDAQ: IMVT) are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves' Disease.

Zacks

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Dec 24

Jan

Feb

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	0 / 1.68M
Day Range	- - -
52 Wk Range	13.08 - 34.47
Market Cap	$2.21B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	24
Short Interest	18.06%
Days to Cover	14.48

About Immunovant Inc

Sector

Health Care

Industry

Biotechnology

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives...

Got Questions? Ask

What is IMVT's 200-day MA?

How is IMVT's operating margin?

What does IMVT's DCF valuation show?

What is IMVT's current price trend?

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Immunovant (IMVT) stock?

You can purchase shares of Immunovant (NASDAQ:IMVT) through any online brokerage.

View our list of the best stock brokerages

Who are Immunovant (IMVT) competitors?

Other companies in Immunovant’s space includes: Twist Bioscience (NASDAQ:TWST), Ultragenyx Pharmaceutical (NASDAQ:RARE), Avidity Biosciences (NASDAQ:RNA), MoonLake (NASDAQ:MLTX) and Ascentage Pharma Group (NASDAQ:AAPG).

What is the forecast, or price target, for Immunovant (IMVT) stock?

Immunovant has a consensus price target of $39.12.

What is the current price for Immunovant (IMVT)?

The stock price for Immunovant (NASDAQ: IMVT) is $13 last updated April 8, 2025 at 5:10 PM EDT.

Does Immunovant (IMVT) pay a dividend?

There are no upcoming dividends for Immunovant.

When is Immunovant (NASDAQ:IMVT) reporting earnings?

Immunovant’s Q4 earnings are confirmed for Wednesday, May 28, 2025.

Is Immunovant (IMVT) going to split?

There is no upcoming split for Immunovant.

What sector and industry does Immunovant (IMVT) operate in?

Immunovant is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.